Compare HSBC Holdings plc (HSBC) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Moderna, Inc. — how do they compare? HSBC Holdings plc trades at $92.98 (market cap $311.92B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: HSBC Holdings plc is far larger — about 4× Moderna, Inc.'s market cap, and HSBC Holdings plc pays a 4.05% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 36 Days and Moderna, Inc. for 59 Days on average.
| HSBC | MRNA | |
|---|---|---|
Market Cap | $311.92B | $78.65B |
Volume | 3,546,658 | 37,373,437 |
Sector | Financials | Health |
52-Week High | $107.86 | $203.46 |
52-Week Low | $65.67 | $22.36 |
Typical Hold Time | 36 Days | 59 Days |
Enterprise Value | $222.19B | $74.80B |
Dividend Yield | 4.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $92.98, down 0.78% today, with a bearish technical signal from moving averages and oscillators. The stock shows solid fundamentals with a P/E of 13.23, net income margin of 34.54%, and ROE of 12.44%. Recent earnings were mixed, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. News highlights strategic moves like expanding in India equity broking and enhancing U.S. Premier services, while the CFO plans to step down in 2027.
The outlook is cautiously optimistic given strong profitability and growth initiatives, but risks include execution challenges from business restructuring and macroeconomic headwinds. Analysts are divided with 38.1% buy ratings, suggesting potential upside if earnings momentum improves, though bearish technicals warrant monitoring near support at $91.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
